Circulating desmosine as a biomarker of azithromycin treatment response: a post hoc analysis of the COLUMBUS randomised controlled trial

James D Chalmers; Remco S Djamin; Marjolijn Schouten; Holly R Keir; Brendan Tan; Joachim G J V Aerts; Jeffrey T-J Huang; Menno van der Eerden

doi:10.1183/23120541.00136-2018

Circulating desmosine as a biomarker of azithromycin treatment response: a post hoc analysis of the COLUMBUS randomised controlled trial

ERJ Open Res. 2018 Nov 12;4(4):00136-2018. doi: 10.1183/23120541.00136-2018. eCollection 2018 Oct.

Authors

James D Chalmers¹, Remco S Djamin², Marjolijn Schouten², Holly R Keir¹, Brendan Tan¹, Joachim G J V Aerts³, Jeffrey T-J Huang¹, Menno van der Eerden³

Affiliations

¹ Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
² Dept of Respiratory Medicine, Amphia Hospital, Breda, The Netherlands.
³ Dept of Respiratory Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands.

Abstract

Circulating desmosine is not reduced by treatment with azithromycin in COPD but elevated desmosine may identify a patient group with a greater treatment response http://ow.ly/vN6N30mhBA1.